Clinical Trial Update: Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating whether CHF 4226 pMDI affects QTc interval in healthy volunteers; the study is completed and sponsored by Chiesi Farmaceutici S.p.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 4226 pMDI

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED